Malaria Diagnostics Market to Grow to USD 1.67 Billion by 2034

Malaria remains one of the world's most significant infectious diseases, caused by Plasmodium parasites (primarily P. falciparum and P. vivax) and transmitted via Anopheles mosquitoes. Despite global progress, malaria continues to impose a heavy burden, particularly in sub-Saharan Africa and Southeast Asia.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73435

Effective diagnosis is critical to control and elimination efforts. The malaria diagnostics market is expanding due to rising adoption of rapid diagnostic tests (RDTs), advancements in molecular platforms, digital/AI surveillance tools, and global malaria eradication initiatives by WHO, CDC, and local governments.

Market Overview
• Market Size (2024): USD 920 million
• Forecast (2034): USD 1.67 billion
• CAGR (2025-2034): 6.2%

Growth is driven by increasing malaria incidence in endemic regions, investment in rapid diagnostics, and development of high-sensitivity molecular assays.

Key Highlights:
• WHO estimates ~249 million malaria cases globally in 2022, with ~608,000 deaths.
• RDTs dominate point-of-care use due to affordability and ease.
• Molecular testing (PCR, LAMP) expanding for high-sensitivity detection.
• AI-driven mapping tools support global malaria elimination goals.

Segmentation Analysis
By Product Type:
• Rapid Diagnostic Tests (RDTs)
o HRP2-based tests (detect P. falciparum)
o pLDH-based tests (detect all species)
o Combination antigen-based tests

• Microscopy
o Giemsa-stained blood smear microscopy (traditional gold standard)
o Digital/automated microscopy (AI-enabled)

• Molecular Diagnostics
o Polymerase Chain Reaction (PCR)
o Loop-Mediated Isothermal Amplification (LAMP)
o Next-Gen Sequencing (NGS - research use)

• Serology & Others
o ELISA-based antibody detection (limited use)
o Biomarker-based novel assays (pipeline)

By Technology:
• Antigen-Detection Lateral Flow RDTs
• Molecular PCR & LAMP Platforms
• AI-Powered Microscopy & Image Analysis
• Mobile App-Based Digital Reporting Systems

By End Use:
• Hospitals & Clinics
• Diagnostic Laboratories
• Public Health Programs & NGOs
• Research Institutes

By Application:
• Plasmodium falciparum Detection
• Plasmodium vivax Detection
• Mixed/Other Species Detection
• Surveillance & Elimination Programs

Segmentation Summary:
RDTs dominate today's market, but molecular diagnostics and AI-driven surveillance tools represent the fastest-growing segments, particularly in research and elimination settings.

Explore Full Report here: https://exactitudeconsultancy.com/reports/73435/malaria-diagnostics-market

Regional Analysis
North America
• ~15% share in 2024.
• Low malaria incidence but significant R&D and funding contributions.
• Strong adoption of molecular platforms for imported malaria cases.
Europe
• ~20% share.
• High involvement in funding global eradication programs.
• EMA supporting novel diagnostic development.
Asia-Pacific
• ~28% share, fast-growing region.
• High malaria burden in India, Indonesia, Myanmar, and Papua New Guinea.
• Expanding diagnostic infrastructure with WHO-led programs.
Middle East & Africa
• Largest market share (~30%).
• Sub-Saharan Africa accounts for ~95% of global malaria cases.
• Strong adoption of RDTs through public health programs.
Latin America
• Brazil, Colombia, and Venezuela major endemic regions.
• Expanding molecular diagnostic use for P. vivax.
Regional Summary:
Africa remains the largest consumer of RDTs, while Asia-Pacific is the fastest-growing due to high burden and infrastructure improvements. North America and Europe drive innovation and funding.

Market Dynamics
Key Growth Drivers:
• Rising malaria prevalence in endemic regions.
• Strong global eradication initiatives by WHO and governments.
• Increasing adoption of RDTs for field diagnosis.
• Expanding molecular diagnostic technologies.

Key Challenges:
• HRP2 gene deletions reducing accuracy of HRP2-based RDTs.
• Limited healthcare infrastructure in rural endemic areas.
• Affordability issues for advanced molecular diagnostics.
• Resistance of parasites to antimalarial drugs complicating control efforts.

Latest Trends:
• Development of next-gen RDTs targeting multiple biomarkers.
• AI-powered digital microscopy for high-throughput diagnosis.
• Mobile app-based malaria reporting systems in Africa and Asia.
• Integration of molecular surveillance into national control programs.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73435

Competitor Analysis
Major Players in the Market:
• Abbott Laboratories (CareStart malaria RDTs)
• SD Biosensor, Inc. (Standard Diagnostics RDTs)
• bioMérieux SA
• Qiagen N.V. (molecular platforms)
• Thermo Fisher Scientific Inc. (PCR assays)
• Meridian Bioscience, Inc.
• Access Bio, Inc.
• Premier Medical Corporation Ltd.
• Mologic Ltd. (now Global Access Diagnostics - lateral flow tests)
• Siemens Healthineers (digital diagnostics and AI integration)

Competitive Summary:
Abbott, SD Biosensor, and Access Bio dominate RDTs. Qiagen, Thermo Fisher, and bioMérieux lead molecular diagnostics. Siemens and Mologic advance AI/digital integration. Competition focuses on sensitivity improvements, cost reduction, and elimination program partnerships.

Conclusion
The Malaria Diagnostics Market, valued at USD 920 million in 2024, is projected to reach USD 1.67 billion by 2034, growing at a CAGR of 6.2%. Expansion of RDTs, molecular diagnostics, and AI-driven surveillance will continue to drive growth.

Key Takeaways:
• RDTs dominate, but molecular and AI-based platforms are gaining traction.
• Africa remains the largest market, while Asia-Pacific grows fastest.
• HRP2 gene deletions driving demand for new diagnostic targets.
• Future breakthroughs will come from next-gen RDTs, AI microscopy, and digital surveillance tools.

The next decade will shift malaria diagnostics from basic antigen detection to integrated AI-powered molecular platforms, creating strong opportunities for diagnostics, biotech, and digital health innovators.

This report is also available in the following languages : Japanese (マラリア診断市場), Korean (말라리아 진단 시장), Chinese (疟疾诊断市场), French (Marché du diagnostic du paludisme), German (Markt für Malariadiagnostik), and Italian (Mercato della diagnostica della malaria), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73435/malaria-diagnostics-market#request-a-sample

Our More Reports:

DNA Methylation Market
https://exactitudeconsultancy.com/reports/73493/dna-methylation-market

miRNA Tools and Services Market
https://exactitudeconsultancy.com/reports/73495/mirna-tools-and-services-market

Bioprocess Analyzers Market
https://exactitudeconsultancy.com/reports/73497/bioprocess-analyzers-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.